Timothy J Williamson1, Susan M Love2, Jessica N Clague DeHart3, Alexandra Jorge-Miller1,4, Leah Eshraghi2, Heather Cooper Ortner2, Annette L Stanton5,6,7,8. 1. Department of Psychology, University of California, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. 2. Dr. Susan Love Research Foundation, Encino, CA, USA. 3. Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. 4. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. 5. Department of Psychology, University of California, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. astanton@ucla.edu. 6. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. astanton@ucla.edu. 7. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. astanton@ucla.edu. 8. Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, CA, USA. astanton@ucla.edu.
Abstract
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors. METHODS: Participants (N = 515) with MBC were recruited from Dr. Susan Love Research Foundation's Army of Women® and other advocacy organizations. Participants completed questionnaires of MBC-related collateral damage, depressive symptoms, anxiety, self-efficacy for managing oncologic treatments and physical symptoms, sleep, and physical activity. RESULTS: Eight domains of MBC-related collateral damage, as well as MBC-related benefit finding, were reliably characterized. Concerns about mortality/uncertainty were most prominent. Participants also endorsed high levels of benefit finding. Participants younger than 50 years, with limited financial resources, or with children under 18 at home reported the most collateral damage. Collateral damage was associated significantly with compromised psychological health, lower illness management efficacy, and poorer health behaviors, beyond sociodemographic and medical characteristics. CONCLUSIONS: Subgroups of MBC patients report long-term, life-altering consequences of MBC and its treatments, which relate to important health outcomes. Clinical implications and recommendations are discussed.
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBCpatients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors. METHODS:Participants (N = 515) with MBC were recruited from Dr. Susan Love Research Foundation's Army of Women® and other advocacy organizations. Participants completed questionnaires of MBC-related collateral damage, depressive symptoms, anxiety, self-efficacy for managing oncologic treatments and physical symptoms, sleep, and physical activity. RESULTS: Eight domains of MBC-related collateral damage, as well as MBC-related benefit finding, were reliably characterized. Concerns about mortality/uncertainty were most prominent. Participants also endorsed high levels of benefit finding. Participants younger than 50 years, with limited financial resources, or with children under 18 at home reported the most collateral damage. Collateral damage was associated significantly with compromised psychological health, lower illness management efficacy, and poorer health behaviors, beyond sociodemographic and medical characteristics. CONCLUSIONS: Subgroups of MBCpatients report long-term, life-altering consequences of MBC and its treatments, which relate to important health outcomes. Clinical implications and recommendations are discussed.
Entities:
Keywords:
Collateral damage; Metastatic breast cancer; Psycho-oncology; Quality of life; Supportive care; Survivorship
Authors: Leslie Bernstein; Mark Allen; Hoda Anton-Culver; Dennis Deapen; Pamela L Horn-Ross; David Peel; Richard Pinder; Peggy Reynolds; Jane Sullivan-Halley; Dee West; William Wright; Al Ziogas; Ronald K Ross Journal: Cancer Causes Control Date: 2002-09 Impact factor: 2.506
Authors: Anthony W Love; Brenda Grabsch; David M Clarke; Sidney Bloch; David W Kissane Journal: Aust N Z J Psychiatry Date: 2004-07 Impact factor: 5.744
Authors: Sindy Oh; Lara Heflin; Beth E Meyerowitz; Katherine A Desmond; Julia H Rowland; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2004-09 Impact factor: 4.872
Authors: Cheryl Koopman; Bita Nouriani; Vanessa Erickson; Renu Anupindi; Lisa D Butler; Michael H Bachmann; Sandra E Sephton; David Spiegel Journal: Breast J Date: 2002 Nov-Dec Impact factor: 2.431
Authors: Sachiko M Oshima; Sarah D Tait; Christel Rushing; Whitney Lane; Terry Hyslop; Anaeze C Offodile; Stephanie B Wheeler; S Yousuf Zafar; Rachel Greenup; Laura J Fish Journal: JCO Oncol Pract Date: 2021-02-10
Authors: Mireia Margelí Vila; Sonia Del Barco Berron; Miguel Gil-Gil; Cristian Ochoa-Arnedo; Rafael Villanueva Vázquez Journal: Breast Date: 2020-06-26 Impact factor: 4.380
Authors: Patricia I Moreno; Fiona S Horner; Joanna B Torzewski; Jessica L Thomas; William Gradishar; David Victorson; Frank J Penedo Journal: Contemp Clin Trials Commun Date: 2021-12-17